Aptahem signs a non binding Term Sheet for development, manufacturing and distribution of Apta-1 for sepsis in Europe
Aptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license terms for exclusive development, manufacturing and distribution of Apta-1 for treatment of sepsis in Europe. The company has decided to publish the information about the NBTS as the signing allows the other party a period to negotiate exclusively with Aptahem. More specific information will be made public if the the transaction will take place with the other party.The signed NBTS includes license terms